Treatment of hepatitis C with interferon and ribavirin
- PMID: 10921409
- DOI: 10.1046/j.1440-1746.2000.02082.x
Treatment of hepatitis C with interferon and ribavirin
Abstract
Hepatitis C is a worldwide problem that frequently results in end-stage liver disease and its complications. Treatment for hepatitis C virus (HCV) has been rather ineffective but several recent studies have clarified the role of interferon and ribavirin therapy. In line with therapeutic progress in HIV infection, hepatitis C is now entering the era of multidrug antiviral therapy. Ribavirin is an orally active synthetic guanosine analogue with theoretical antiviral and immunomodulatory actions. In this review we have evaluated the role of interferon and ribavirin in treatment-naive patients, relapsers and non-responders. In naive patients the combination results in improved end-of-treatment and sustained response rates, with an overall 41% sustained virological response rate in patients treated for 48 weeks. Therapeutic benefit also extends to the traditionally difficult to treat patients (genotype 1, high vital load and advanced fibrosis). The addition of ribavirin to interferon has also resulted in an increased toxicity profile, which has made therapy more difficult for both the patient and managing physician. However, the significant improvement in response rates for all patients makes combination therapy the most appropriate choice as the first-line therapy for suitable patients with chronic viral hepatitis C. Appropriate management with interferon and ribavirin includes assessing the patient's HCV genotype to determine the optimal duration of therapy, assessing therapeutic efficacy by measuring HCV-RNA at 24 weeks and monitoring for the additional ribavirin side-effects.
Similar articles
-
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.AIDS. 2004 Jan 2;18(1):75-9. doi: 10.1097/00002030-200401020-00009. AIDS. 2004. PMID: 15090832
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4. Lancet. 1998. PMID: 9807989 Clinical Trial.
-
Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.J Hepatol. 2000 Sep;33(3):448-55. doi: 10.1016/s0168-8278(00)80281-0. J Hepatol. 2000. PMID: 11020001 Clinical Trial.
-
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review.
-
Treatment of hepatitis C virus infection.World J Gastroenterol. 2007 Apr 7;13(13):1897-905. doi: 10.3748/wjg.v13.i13.1897. World J Gastroenterol. 2007. PMID: 17461488 Free PMC article. Review.
Cited by
-
Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran.Hepat Mon. 2013 Jun 23;13(6):e11038. doi: 10.5812/hepatmon.11038. eCollection 2013. Hepat Mon. 2013. PMID: 24032043 Free PMC article.
-
Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.Inflammopharmacology. 2010 Apr;18(2):87-94. doi: 10.1007/s10787-009-0027-7. Epub 2010 Jan 14. Inflammopharmacology. 2010. PMID: 20069380
-
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02587-17. doi: 10.1128/AAC.02587-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29439971 Free PMC article. Clinical Trial.
-
Personal health records: evaluation of functionality and utility.J Am Med Inform Assoc. 2002 Mar-Apr;9(2):171-80. doi: 10.1197/jamia.m0978. J Am Med Inform Assoc. 2002. PMID: 11861632 Free PMC article.
-
Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats.Drug Target Insights. 2007;2:19-27. Epub 2007 Feb 7. Drug Target Insights. 2007. PMID: 21901059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources